

# Filippo Milano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9931029/publications.pdf>

Version: 2024-02-01

29  
papers

1,327  
citations

567281

15  
h-index

526287

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1802  
citing authors

#	ARTICLE	IF	CITATIONS
1	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8.	1.2	12
2	Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. <i>Blood</i> , 2022, 139, 1694-1706.	1.4	36
3	Correlation of initial upper respiratory tract viral burden with progression to lower tract disease in adult allogeneic hematopoietic cell transplant recipients. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105152.	3.1	5
4	Utility of the Treatment-Related Mortality (TRM) Score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2022, 36, 1563-1574.	7.2	2
5	Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 286-291.	1.2	10
6	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. <i>Blood</i> , 2021, 138, 273-282.	1.4	88
7	Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 540-544.	1.2	11
8	Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients. <i>Blood Advances</i> , 2021, 5, 3113-3119.	5.2	24
9	Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. <i>Blood Advances</i> , 2021, 5, 4064-4072.	5.2	17
10	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8.	1.2	4
11	Guidelines for Cord Blood Unit Selection. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2190-2196.	2.0	44
12	Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. <i>Blood Advances</i> , 2020, 4, 3302-3310.	5.2	11
13	Pain Management in Childhood Leukemia: Diagnosis and Available Analgesic Treatments. <i>Cancers</i> , 2020, 12, 3671.	3.7	10
14	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1312-1317.	2.0	49
15	Improved Survival after Cord Blood Transplantation: Single-Center Experience in Pediatric Patients Over a 2-Decade Period. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e117-e118.	2.0	0
16	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1045-1052.	2.0	19
17	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
18	Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 484-493.	2.3	7

#	ARTICLE	IF	CITATIONS
19	A Modified Intensive Strategy to Prevent Cytomegalovirus Disease in Seropositive Umbilical Cord Blood Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2094-2100.	2.0	23
20	Reply to Author. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2166.	2.0	0
21	Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 654-658.	2.0	14
22	Real Time Immunophenotyping of Leukocyte Subsets Early after Double Cord Blood Transplantation Predicts Graft Function. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 412-419.	2.0	1
23	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016, 375, 944-953.	27.0	352
24	Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. <i>Lancet Haematology</i> , 2016, 3, e330-e339.	4.6	26
25	Stem cell comparison: what can we learn clinically from unrelated cord blood transplantation as an alternative stem cell source?. <i>Cytotherapy</i> , 2015, 17, 695-701.	0.7	4
26	Late-Onset Colitis after Cord Blood Transplantation Is Consistent with Graft-Versus-Host Disease: Results of a Blinded Histopathological Review. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1008-1013.	2.0	48
27	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 549-555.	2.0	47
28	Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. <i>Blood</i> , 2011, 118, 5689-5696.	1.4	94
29	Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 1190-1197.	1.6	351